Sandmaier Brenda M, Fukuda Takahiro, Gooley Theodore, Yu Cong, Santos Erlinda B, Storb Rainer
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., D1-100, PO Box 19024, Seattle, WA 98109-1024, USA.
Exp Hematol. 2003 Feb;31(2):168-75. doi: 10.1016/s0301-472x(02)01022-6.
We previously described a nonmyeloablative hematopoietic stem cell transplantation regimen in dog leukocyte antigen (DLA)-identical littermate recipients consisting of low-dose total body irradiation (TBI) before and mycophenolate mofetil (MMF)/cyclosporine (CSP) given after transplant to control both graft-vs-host and residual host-vs-graft reactions. In this study, we sought to develop a reduced-intensity regimen to achieve engraftment across major histocompatibility complex barriers in DLA-haploidentical littermate recipients.
We tested a regimen of 450-cGy TBI with or without postgrafting MMF/CSP for 28 and 35 days, respectively, and with the administration of monoclonal antibody (mAb) S5 (anti-CD44), at a dose of 0.2 mg/kg/day from days -7 through -2, prior to receiving TBI.
One of six dogs conditioned with 450-cGy TBI alone achieved engraftment of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Three of six dogs achieved sustained donor cell engraftment using 450-cGy TBI and posttransplantation MMF/CSP. None of three dogs given mAb S5 followed by 450-cGy TBI showed signs of donor cell engraftment. However, when S5 mAb pretreatment was added to 450-cGy TBI and postgrafting MMF/CSP, 10 of 12 dogs achieved sustained engraftment (p = 0.008 or 0.007 vs 450-cGy alone or to S5 + 450-cGy TBI without MMF/CSP, respectively), with only three dogs developing severe graft-vs-host disease on this short regimen of immunosuppression.
These results show that engraftment across a DLA haplotype-mismatched barrier can be achieved after reduced-intensity conditioning when mAb S5 directed at CD44 is added to this regimen.
我们之前描述了一种在犬白细胞抗原(DLA)相同的同窝受体中进行的非清髓性造血干细胞移植方案,该方案包括移植前低剂量全身照射(TBI)以及移植后给予霉酚酸酯(MMF)/环孢素(CSP),以控制移植物抗宿主反应和残留的宿主抗移植物反应。在本研究中,我们试图开发一种降低强度的方案,以在DLA单倍型相同的同窝受体中跨越主要组织相容性复合体屏障实现植入。
我们测试了一种方案,即450 cGy的TBI,分别联合或不联合移植后28天和35天的MMF/CSP,并在接受TBI前从第-7天至-2天给予剂量为0.2 mg/kg/天的单克隆抗体(mAb)S5(抗CD44)。
仅接受450 cGy TBI预处理的6只犬中有1只实现了粒细胞集落刺激因子动员的外周血干细胞植入。使用450 cGy TBI和移植后MMF/CSP,6只犬中有3只实现了供体细胞的持续植入。给予mAb S5后再进行450 cGy TBI的3只犬均未显示供体细胞植入的迹象。然而,当将S5 mAb预处理添加到450 cGy TBI和移植后MMF/CSP时,12只犬中有10只实现了持续植入(分别与单独使用450 cGy或S5 + 450 cGy TBI但不使用MMF/CSP相比,p = 0.008或0.007),在这种短期免疫抑制方案下只有3只犬发生了严重的移植物抗宿主病。
这些结果表明,当将针对CD44的mAb S5添加到该方案中时,降低强度预处理后可跨越DLA单倍型不匹配的屏障实现植入。